The relationship of plasma Aβ levels to dementia in aging individuals with down syndrome

Alzheimer Disease and Associated Disorders

Volumn 23, Issue 4, 2009, Pages 315-318

  Matsuoka, Yasuji ^a   Andrews, Howard F ^b   Becker, Amanda G ^a   Gray, Audrey J ^a   Mehta, Pankaj D ^c   Sano, Mary C ^d   Dalton, Arthur J ^c   Aisen, Paul S ^a,e  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^b Columbia University College of Physicians and Surgeons ^*  (United States)

^c NEW YORK STATE INSTITUTE FOR BASIC RESEARCH IN DEVELOPMENTAL DISABILITIES   (United States)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

A ; A 40 42 ratio; Alzheimer disease; Dementia; Down syndrome

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E; PRESENILIN; AMYLOID BETA PROTEIN;

ADULT; AGING; AMYLOID BETA PROTEIN BLOOD LEVEL; ARTICLE; COGNITION; CONTROLLED STUDY; CORRELATIONAL STUDY; DEMENTIA; DISEASE SEVERITY; DOWN SYNDROME; FEMALE; GENDER; GENE MUTATION; GENETIC SUSCEPTIBILITY; GENOTYPE; GROUPS BY AGE; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DEFICIENCY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; AGED; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; GENETICS; INTERNATIONAL COOPERATION; MIDDLE AGED; MULTICENTER STUDY;

AGED; AGING; AMYLOID BETA-PROTEIN; DEMENTIA; DOWN SYNDROME; FEMALE; HUMANS; INTERNATIONALITY; MALE; MIDDLE AGED;

EID: 75949089358     PISSN: 08930341     EISSN: None     Source Type: Journal    
DOI: 10.1097/WAD.0b013e3181aba61e     Document Type: Article

References (26)

1. Prasher VP, Farrer MJ, Kessling AM, et al. Molecular mapping of Alzheimer-type dementia in Down's syndrome. Ann Neurol. 1998;43:380-383.
2. Fukumoto H, Tennis M, Locascio JJ, et al. Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels. Arch Neurol. 2003;60:958-964.
3. Scheuner D, Eckman C, Jensen M, et al. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med. 1996;2:864-870.
4. Mehta PD, Dalton AJ, Mehta SP, et al. Increased plasma amyloid beta protein 1-42 levels in Down syndrome. Neuroscience Letters. 1998;241:13-16.
5. Cavani S, Tamaoka A, Moretti A, et al. Plasma levels of amyloid beta 40 and 42 are independent from ApoE genotype and mental retardation in Down syndrome. Am J Med Genet. 2000;95:224-228.
6. Schupf N, Patel B, Silverman W, et al. Elevated plasma amyloid beta-peptide 1-42 and onset of dementia in adults with Down syndrome. Neurosci Lett. 2001;301:199-203.
7. Mehta PD, Mehta SP, Fedor B, et al. Plasma amyloid beta protein 1-42 levels are increased in old Down Syndrome but not in young Down Syndrome. Neurosci Lett. 2003;342: 155-158.
8. Horikoshi Y, Sakaguchi G, Becker AG, et al. Development of Abeta terminal end-specific antibodies and sensitive ELISA for Abeta variant. Biochem Biophys Res Commun. 2004;319: 733-737.
9. Aisen PS, Dalton AJ, Sano M, et al. Design and implementation of a multicenter trial of vitamin E in aging individuals with Down syndrome. J Policy Pract Intellect Disabil. 2005;2:86-93.
10. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Vol 4. Washington, DC: American Psychiatric Association; 1994.
11. DYSPRAXIA scale for adults with Down syndrome (computer program). Version: Available from A.J. Dalton, NYS Institute for Basic Research in Developmental Disabilities, 1050 Forest Hill Road, Staten Island, New York, 10314; 1997.
12. Sano M, Aisen PS, Dalton AJ, et al. Assessment of aging individuals with Down syndrome in clinical trials: results of baseline measures. J Policy Pract Intellect Disabil. 2005; 2:126-138.
13. Mehta PD, Patrick BA, Pirttila T, et al. Detection of apolipoprotein E phenotype in unconcentrated cerebrospinal fluid. J Clin Lab Anal. 2003;17:18-21.
14. Kumar-Singh S, Theuns J, Van Broeck B, et al. Mean ageof- onset of familial alzheimer disease caused by presenilin mutations correlates with both increased Abeta42 and decreased Abeta40. Hum Mutat. 2006;27:686-695.
15. Bentahir M, Nyabi O, Verhamme J, et al. Presenilin clinical mutations can affect gamma-secretase activity by different mechanisms. J Neurochem. 2006;96:732-742.
16. van Oijen M, Hofman A, Soares HD, et al. Plasma Abeta(1-40) and Abeta(1-42) and the risk of dementia: a prospective case-cohort study. Lancet Neurol. 2006;5:655-660.
17. Mayeux R, Honig LS, Tang MX, et al. Plasma A(beta)40 and A(beta)42 and Alzheimer's disease: relation to age, mortality, and risk. Neurology. 2003;61:1185-1190.
18. Sobow T, Flirski M, Kloszewska I, et al. Plasma levels of alpha beta peptides are altered in amnestic mild cognitive impairment but not in sporadic Alzheimer's disease. Acta Neurobiol Exp (Wars). 2005;65:117-124.
19. Odetti P, Piccini A, Giliberto L, et al. Plasma levels of insulin and amyloid beta 42 are correlated in patients with amnestic mild cognitive impairment. J Alzheimers Dis. 2005;8: 243-245.
20. Assini A, Cammarata S, Vitali A, et al. Plasma levels of amyloid beta-protein 42 are increased in women with mild cognitive impairment. Neurology. 2004;63:828-831.
21. Mehta PD, Pirttila T, Mehta SP, et al. Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease. Arch Neurol. 2000;57:100-105.
22. Vanderstichele H, Van Kerschaver E, Hesse C, et al. Standardization of measurement of beta-amyloid(1-42) in cerebrospinal fluid and plasma. Amyloid. 2000;7:245-258.
23. Kulstad JJ, Green PS, Cook DG, et al. Differential modulation of plasma beta-amyloid by insulin in patients with Alzheimer disease. Neurology. 2006;66:1506-1510.
24. Iwatsubo T. Amyloid beta protein in plasma as a diagnostic marker for Alzheimer's disease. Neurobiol Aging. 1998;19: 161-163.
25. Pesaresi M, Lovati C, Bertora P, et al. Plasma levels of betaamyloid (1-42) in Alzheimer's disease and mild cognitive impairment. Neurobiol Aging. 2006;27:904-905. (Pubitemid 44287903)
26. Schupf N, Patel B, Pang D, et al. Elevated plasma betaamyloid peptide Abeta(42) levels, incident dementia, and mortality in Down syndrome. Arch Neurol. 2007;64:1007-1013.